Objectives: A nasal spray of dihydroergotamine was developed for the treatment of migraine headaches, and pharmacokinetic studies were scheduled to evaluate the bioavailability of dihydroergotamine by this new route of administration.
Methods: Nine studies were performed with dihydroergotamine administered by nasal spray to evaluate the bioavailability of the nasal route versus the intramuscular route, the linearity of the kinetics, the interindividual and intraindividual variations, and the influence of different factors.
Results: Nasally administered dihydroergotamine (1 mg) becomes rapidly available to the systemic circulation, with peak plasma levels of 1 ng/ml achieved in 0.9 hour. The relative bioavailability versus intramuscular route is 38.4%. Dihydroergotamine administered by the nasal route exhibits linear dose proportionality (1 to 4 mg). Intraindividual variations of bioavailability evaluated for a 1-year period were higher (29%) than those found for the intramuscular route (20%) but comparable to the oral route. Interindividual variations for bioavailability were greater (25% versus 14% by the intramuscular route) but comparable to the oral route. Caffeine contained in the nasal solution (1%) had no effect on the absorption. Vasomotor phenomena, which could also affect the nasal mucosa during a migraine headache, do not modify the bioavailability. The constriction of the nasal mucosa by fenoxazoline leads to a slight decrease (-15%) in the bioavailability. The presence of acute viral rhinitis did not result in any change in dihydroergotamine nasal absorption compared with the normal state of the nasal mucosa. From a pharmacokinetic point of view, nasally administered dihydroergotamine can be given, without risk of overdose, to patients receiving long-term oral dihydroergotamine medication.
Conclusion: These results show the reliability and reproducibility of this route of dihydroergotamine administration adapted for the treatment of migraine headaches.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0009-9236(96)90053-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of mRNA formulated with lipid nanoparticles on the transcriptomic and epigenetic profiles of F4/80 liver-associated macrophages.
Sci Rep
January 2025
Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center-Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
Delivery of an mRNA formulated with lipid nanoparticles (LNPs) induces robust humoral and cell-mediated branches of the immune response. Depending on the LNP formula, mRNA encoding proteins can be detected in the liver upon intramuscular administration of mRNA/LNP in mice. This study investigated the impact of mRNA/LNP administration on liver-associated macrophages at the transcriptomic and epigenetic levels in a mouse model.
View Article and Find Full Text PDFA Small-Particle Aerosol Model of Ebolavirus Zaire Infection in Ferrets.
Viruses
November 2024
Viral Immunology Branch, Virology Division, U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
The Ebola virus (EBOV) causes severe disease in humans, and animal models are needed to evaluate the efficacy of vaccines and therapeutics. While non-human primate (NHP) and rodent EBOV infection models have been well characterized, there is a growing need for an intermediate model. Here, we provide the first report of a small-particle aerosol (AE) EBOV ferret model and disease progression compared with the intramuscular (IM) EBOV ferret model.
View Article and Find Full Text PDFDevelopment, Pre-Clinical Safety, and Immune Profile of RENOVAC-A Dimer RBD-Based Anti-Coronavirus Subunit Vaccine.
Vaccines (Basel)
December 2024
Center for Advanced Technologies, Tashkent 100174, Uzbekistan.
The development of effective and safe vaccines and their timely delivery to the public play a crucial role in preventing and managing infectious diseases. Many vaccines have been produced and distributed globally to prevent COVID-19 infection. However, establishing effective vaccine development platforms and evaluating their safety and immunogenicity remains critical to increasing health security, especially in developing countries.
View Article and Find Full Text PDFSince its introduction, vaccination has heavily improved health outcomes. However, implementing vaccination efforts can be challenging, particularly in low and middle-income countries with warmer climates. Microneedle technology has been developed for its simple and relatively painless applications of vaccines.
View Article and Find Full Text PDFEffectiveness of aspiration and the occurrence of adverse effects using the intramuscular route in adults: a systematic review protocol.
JBI Evid Synth
January 2025
School of Nursing of the University of Minho, Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra (Esenfc), Coimbra, Portugal.
Objective: The objective of this review will be to evaluate the effect of prior aspiration versus non-aspiration during intramuscular injection on the occurrence of adverse effects in adult patients.
Introduction: Aspiration is a procedure conducted prior to the administration of intramuscular medications that aims to ensure that the needle tip is inserted in the proper place. Although aspiration is a common procedure, questions have been raised about adverse effects.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!